KALA Stock: Dilution, SEC Filings & News – KALA BIO

KALA KALA BIO, Inc.

Price$0.18

Company About

Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

NASDAQ Global Select

Vol Avg.

1.52 M

Inst Own

Float & OS

Cash/Shr

Market Cap & Ev

3.43 M / -3.03 M

Short Interest

Borrow Rate

Days to Cover

Overall Offering Risk

Warrant Exercise Risk

Research Report

Customize research

Recent Articles (8)

View All

Highway Holdings Limited Announces Closing of $7.0 Million Strategic Investment by David Lazar and Planned Spin-Off of Its Legacy Business to Existing Shareholders

PRNewswire

Nov 5, 2026, 7:00 AM

KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception

Newsfile

Sep 29, 2026, 7:30 AM

Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products

Globe Newswire

Sep 24, 2026, 7:30 AM

KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team

Globe Newswire

Sep 17, 2026, 7:30 AM

Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Globe Newswire

Sep 3, 2026, 8:30 AM

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Globe Newswire

Sep 1, 2026, 7:45 AM

KALA BIO Announces Reverse Stock Split

Globe Newswire

May 7, 2026, 9:00 AM

Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments

Globe Newswire

Apr 28, 2026, 8:00 AM

Recent Filings

View All

Type	Title	Date Released
8-K	KALA BIO Provides CEO Update and Reports Preliminary Third Quarter 2026 Financial Results New	Nov 9, 2026, 9:01 AM
8-K	KALA BIO, INC. Announces Voting Results from Annual Meeting of Stockholders	Nov 3, 2026, 4:11 PM
SCHEDULE 13G	Labkowski Nachum (Filed by)	Oct 19, 2026, 9:09 AM
DEF 14A	Form DEF 14A	Sep 24, 2026, 4:10 PM
PRE 14A	Form PRE 14A	Sep 11, 2026, 4:56 PM
8-K	KALA BIO Enters Exclusive Distribution and Reseller Agreement with Virotek for Ophthalmology Genetic Testing Program	Sep 10, 2026, 5:24 PM
8-K	KALA BIO Sets Date for 2026 Annual Meeting of Stockholders and Establishes Stockholder Proposal Deadlines	Sep 9, 2026, 5:06 PM
8-K	KALA BIO, Inc. Receives Nasdaq Delisting Notice Regarding Minimum Bid Price Requirement	Aug 28, 2026, 6:45 AM
10-Q	Form 10-Q	Aug 19, 2026, 4:16 PM
NT 10-Q	Form NT 10-Q	Aug 14, 2026, 10:14 AM
8-K	KALA BIO, Inc. Files Prospectus Supplement for Securities Offering	Jul 22, 2026, 8:13 PM
424B5	[No Baby Shelf]* July 2026 ATM \| Offering amount: $250,000,000 \| Bank: H.C. Wainwright & Co.	Jul 22, 2026, 5:13 PM

Earnings

Nov

Q4 2026 Earnings reportUpcoming

Aug

Q3 2026 Earnings report

-21.32%missed

May

Q2 2026 Earnings report

-0.14%beat

Apr

Q2 2026 Earnings report

0.08%beat

Nov

Q4 2025 Earnings report

-1.07%beat

Aug

Q3 2025 Earnings report

-85.50%beat

Related Healthcare stocks

All tickers

KALA BIO, Inc. KALA

Related Healthcare stocks

Related Healthcare stocks